1. A 22-year-old man is admitted during a first psychotic episode with prominent auditory hallucinations and persecutory delusions. He is started on an antipsychotic. His family asks which of his symptoms is most likely to improve with this treatment. Which symptom dimension is, as a group, the most responsive to antipsychotic therapy?
A) His blunted affect and social withdrawal
B) His hallucinations and delusions
C) His deficits in working memory and processing speed
D) His reduced motivation and goal-directed behavior
E) His diminished capacity to experience pleasure
ANSWER: B
Rationale:
Positive symptoms — hallucinations and delusions — are most directly linked to mesolimbic dopamine hyperactivity and are, as a group, the dimension most responsive to antipsychotic treatment; first-episode patients typically show substantial positive-symptom reduction within weeks. This is the realistic expectation to convey to the family.
Option A: Option A is incorrect because blunted affect and social withdrawal are negative symptoms, which respond poorly to antipsychotics and reflect the mesocortical dopamine deficit.
Option C: Option C is incorrect because cognitive deficits show no robust response to antipsychotics beyond what follows from reduced positive symptoms.
Option D: Option D is incorrect because avolition is a negative symptom that is among the least treatment-responsive.
Option E: Option E is incorrect because anhedonia is likewise a negative-symptom domain that responds poorly to dopamine blockade.
2. A 25-year-old woman stabilized on haloperidol returns after two months reporting that her menstrual periods have stopped and she has noticed milk discharge from both breasts. A pregnancy test is negative and her prolactin is markedly elevated. Which explanation and management approach is best supported?
A) Haloperidol's blockade of D2 receptors in the tuberoinfundibular pathway has removed dopamine's tonic inhibition of prolactin, causing hyperprolactinemia; switching to an antipsychotic that produces less prolactin elevation is a rational management step
B) The findings reflect nigrostriatal D2 blockade and should be managed by adding an anticholinergic
C) The elevated prolactin is from histamine H1 blockade and will resolve with continued dosing as tolerance develops
D) The symptoms indicate alpha-1 blockade and should be managed by slow dose titration
E) The findings reflect 5-HT2A blockade and require no change because they are protective
ANSWER: A
Rationale:
Dopamine from the tuberoinfundibular pathway tonically inhibits pituitary prolactin secretion; haloperidol's D2 blockade there removes that inhibition and raises prolactin, producing amenorrhea and galactorrhea. Because this pathway does not develop tolerance to D2 blockade, the elevation tends to persist, so switching to a lower-prolactin agent is a sound strategy.
Option B: Option B is incorrect because nigrostriatal blockade produces movement effects, not hyperprolactinemia, and anticholinergics do not treat it.
Option C: Option C is incorrect because prolactin elevation arises from D2 blockade, not H1 blockade, and does not attenuate with continued treatment in this pathway.
Option D: Option D is incorrect because orthostatic symptoms, not hyperprolactinemia, stem from alpha-1 blockade.
Option E: Option E is incorrect because the findings reflect D2 blockade and are clinically significant rather than protective.
3. A 30-year-old man started on haloperidol three days ago develops a stiff, mask-like face, reduced arm swing, a pill-rolling tremor, and an episode of sustained involuntary neck muscle contraction. Blockade of D2 receptors in which pathway most directly accounts for these movement findings?
A) The mesolimbic pathway
B) The mesocortical pathway
C) The tuberoinfundibular pathway
D) The nigrostriatal pathway
E) The corticospinal pathway
ANSWER: D
Rationale:
The patient's parkinsonism (mask-like face, reduced arm swing, tremor) and acute dystonia (sustained neck contraction) are extrapyramidal symptoms produced by D2 blockade in the nigrostriatal pathway, which mimics the dopamine-deficient state of the motor system. High-potency agents such as haloperidol carry a high extrapyramidal risk because of their tight D2 binding with little offsetting receptor activity.
Option A: Option A is incorrect because mesolimbic blockade suppresses positive symptoms rather than causing movement effects.
Option B: Option B is incorrect because the mesocortical pathway relates to negative and cognitive symptoms.
Option C: Option C is incorrect because the tuberoinfundibular pathway governs prolactin, not movement.
Option E: Option E is incorrect because the corticospinal tract is a motor pathway unrelated to dopaminergic projection systems and is not the basis of drug-induced extrapyramidal symptoms.
4. A 28-year-old man has had full resolution of hallucinations and delusions on his current antipsychotic, with no extrapyramidal signs and no sedation. He remains markedly unmotivated, withdrawn, and emotionally flat, and these features are limiting his return to work. Which interpretation and management approach is best supported for this clinical picture?
A) These are residual positive symptoms requiring a higher antipsychotic dose
B) These are extrapyramidal akinesia and should be treated with an anticholinergic
C) These are primary negative symptoms; among available agents, cariprazine and lurasidone have the most robust evidence for benefit, and early psychosocial rehabilitation should be combined with pharmacotherapy
D) These are signs of hyperprolactinemia and should be managed by lowering the dose
E) These represent normal recovery and require no intervention
ANSWER: C
Rationale:
With positive symptoms resolved and no extrapyramidal signs or sedation to account for the picture, the persistent avolition, asociality, and blunted affect are best understood as primary negative symptoms reflecting the mesocortical dopamine deficit. Among available agents, cariprazine and lurasidone carry the most robust evidence for primary negative symptoms, and psychosocial rehabilitation should be started early as an additive component.
Option A: Option A is incorrect because the positive symptoms have resolved and dose escalation does not address primary negative symptoms.
Option B: Option B is incorrect because there are no extrapyramidal signs, so akinesia is not the explanation and an anticholinergic would add cognitive burden.
Option D: Option D is incorrect because the picture is not hyperprolactinemia.
Option E: Option E is incorrect because primary negative symptoms cause substantial functional disability and warrant active management rather than observation.
5. A 35-year-old woman with schizophrenia has completed two separate antipsychotic trials, each at an adequate dose for an adequate duration, with documentation confirming adequate striatal D2 occupancy. She continues to have disabling hallucinations and delusions. What is the most appropriate next step?
A) Recognize treatment-resistant schizophrenia and offer clozapine, which has the strongest evidence base for this category
B) Add a third standard antipsychotic at the same occupancy already shown to be ineffective
C) Stop all antipsychotics, since persistent symptoms indicate they cannot help her
D) Add a high-dose anticholinergic to suppress the hallucinations
E) Reduce the antipsychotic dose to lower prolactin and reassess the psychosis
ANSWER: A
Rationale:
Persistent positive symptoms despite two adequate trials at confirmed adequate D2 occupancy meet the definition of treatment-resistant schizophrenia, and clozapine has the strongest evidence base for this group — making it the appropriate next step rather than another standard agent.
Option B: Option B is incorrect because adding a third agent at an occupancy already shown ineffective does not address the resistance and is not the evidence-based move.
Option C: Option C is incorrect because treatment resistance does not mean antipsychotics are futile; it specifically indicates a clozapine trial.
Option D: Option D is incorrect because anticholinergics do not treat psychosis and add cognitive burden.
Option E: Option E is incorrect because lowering the dose does not address the resistant positive symptoms and risks worsening them.
6. A 40-year-old man treated with olanzapine for the past year has gained 14 kg, and new laboratory studies show an elevated fasting glucose and an abnormal lipid panel. His psychosis is well controlled. Which statement best characterizes this development?
A) This is an extrapyramidal complication typical of high-potency first-generation agents
B) This is hyperprolactinemia and explains the weight and laboratory changes
C) This is an anticholinergic effect requiring discontinuation of a co-prescribed agent
D) This is an expected benefit of therapy and requires no monitoring
E) This is the metabolic adverse-effect cluster — weight gain, glucose dysregulation, and dyslipidemia — that is concentrated in second-generation agents and most pronounced with olanzapine and clozapine
ANSWER: E
Rationale:
Weight gain, glucose dysregulation, and dyslipidemia constitute the metabolic adverse-effect cluster that is concentrated in the second-generation class and is most pronounced with olanzapine and clozapine; recognizing this agent-linked pattern is essential because it represents a major long-term safety concern requiring active metabolic monitoring and possible agent reconsideration.
Option A: Option A is incorrect because the findings are metabolic, not extrapyramidal, and are characteristic of second-generation rather than high-potency first-generation agents.
Option B: Option B is incorrect because hyperprolactinemia does not explain glucose and lipid abnormalities or this degree of weight gain.
Option C: Option C is incorrect because the cluster is a direct metabolic effect of the agent, not an anticholinergic interaction.
Option D: Option D is incorrect because these are harmful effects that demand monitoring, not a benefit.
7. A 74-year-old woman taking an antihypertensive is started on a low-potency antipsychotic. Within days she reports dizziness and near-fainting when she stands, and a measured drop in blood pressure on standing is documented. Which mechanism and management approach best fits this presentation?
A) Nigrostriatal D2 blockade causing akathisia, managed by adding a stimulant
B) Alpha-1 adrenergic blockade causing orthostatic hypotension, an effect additive with her antihypertensive and especially dangerous in an older adult; starting low and titrating the dose gradually is the primary management strategy
C) Histamine H1 blockade causing the blood-pressure drop, managed by increasing the dose quickly
D) Tuberoinfundibular blockade causing the symptoms, managed with a dopamine agonist
E) Muscarinic blockade causing the hypotension, managed by fluid restriction
ANSWER: B
Rationale:
Low-potency antipsychotics carry significant alpha-1 adrenergic blocking activity, which impairs the reflex maintenance of blood pressure on standing and produces orthostatic hypotension; in an older adult also taking an antihypertensive, the effect is additive and raises the risk of falls and syncope. Starting at a low dose and titrating gradually allows partial tolerance to develop and is the primary management strategy.
Option A: Option A is incorrect because the picture is orthostatic hypotension, not akathisia, and stimulants are not the management.
Option C: Option C is incorrect because orthostatic hypotension arises from alpha-1, not H1, blockade, and rapid dose escalation would worsen it.
Option D: Option D is incorrect because the tuberoinfundibular pathway governs prolactin, not blood pressure.
Option E: Option E is incorrect because the mechanism is alpha-1 blockade rather than muscarinic blockade, and fluid restriction would aggravate orthostasis.
8. A 60-year-old man with schizophrenia on a high-potency first-generation antipsychotic was started on routine prophylactic benztropine to prevent extrapyramidal symptoms. Over the following weeks his family reports he is more forgetful and mentally foggy, and bedside testing confirms worsened cognition. Which explanation and management approach is best supported?
A) The benztropine has raised prolactin, impairing cognition; lower the antipsychotic dose
B) The benztropine is blocking 5-HT2A receptors, worsening cognition; increase its dose
C) The cognitive change reflects nigrostriatal blockade and should prompt adding a second anticholinergic
D) Central muscarinic M1 blockade from benztropine is worsening the cognitive deficits already present in schizophrenia; anticholinergics should be used at the lowest effective dose for the shortest period, with consideration of switching to a lower-extrapyramidal agent rather than continuing routine prophylaxis
E) The change is unrelated to medication and requires no adjustment
ANSWER: D
Rationale:
Benztropine's central muscarinic M1 blockade impairs cognition, and because schizophrenia already carries a cognitive-deficit dimension, routine prophylactic anticholinergic use compounds that impairment. The supported approach is to minimize anticholinergic exposure — lowest effective dose, shortest duration — and to consider switching to a lower-extrapyramidal agent rather than continuing routine prophylaxis.
Option A: Option A is incorrect because anticholinergics do not raise prolactin and the mechanism here is central muscarinic blockade.
Option B: Option B is incorrect because benztropine's relevant action is muscarinic blockade, not 5-HT2A blockade, and increasing it would worsen cognition.
Option C: Option C is incorrect because the cognitive change is anticholinergic, not a nigrostriatal effect, and adding more anticholinergic burden is harmful.
Option E: Option E is incorrect because the temporal link to benztropine and the confirmed cognitive decline make a medication effect the likely cause.
9. A 26-year-old man developed prominent extrapyramidal symptoms on a high-potency first-generation antipsychotic and needs an agent that will still control his psychosis but with a lower likelihood of recurrent movement effects. Based on receptor pharmacology, which selection rationale is best supported?
A) Choose a second-generation agent with a high 5-HT2A-to-D2 affinity ratio, because its 5-HT2A blockade disinhibits striatal dopamine release and raises the threshold for extrapyramidal symptoms even at comparable D2 occupancy
B) Choose another high-potency first-generation agent, since potency does not affect extrapyramidal risk
C) Add a stimulant to a high-potency first-generation agent to counteract the extrapyramidal symptoms
D) Choose an agent specifically for its strong alpha-1 blockade to prevent extrapyramidal symptoms
E) Choose an agent for its high histamine H1 affinity, because sedation prevents extrapyramidal symptoms
ANSWER: A
Rationale:
An agent with a high 5-HT2A-to-D2 affinity ratio is the rational choice because cortical and striatal 5-HT2A blockade disinhibits dopamine release, partially offsetting nigrostriatal D2 blockade and raising the extrapyramidal threshold even at comparable D2 occupancy. This is the core mechanistic rationale distinguishing the lower motor liability of many second-generation agents.
Option B: Option B is incorrect because high-potency first-generation agents share the tight, largely unopposed D2 binding that produced the patient's extrapyramidal symptoms.
Option C: Option C is incorrect because stimulants are not a management for drug-induced extrapyramidal symptoms and could worsen psychosis.
Option D: Option D is incorrect because alpha-1 blockade governs orthostasis, not extrapyramidal risk.
Option E: Option E is incorrect because H1-mediated sedation does not prevent extrapyramidal symptoms.
10. A 33-year-old man on a standard dose of a high-potency first-generation antipsychotic has partially controlled but residual symptoms. The covering team proposes simply doubling his dose to push for more benefit. Based on the D2 occupancy relationship, what is the most likely result of that approach, and what is the better reasoning?
A) Doubling the dose will increase efficacy proportionally with no added risk, so it is the best option
B) Doubling the dose will lower his prolactin and improve symptoms
C) At a standard dose a high-potency agent already produces occupancy near the top of the 65 to 80 percent therapeutic window, so doubling it pushes occupancy past about 80 percent and adds extrapyramidal symptoms without meaningful added antipsychotic benefit; reassessing adherence, diagnosis, and a possible switch is the better course
D) Doubling the dose will eliminate extrapyramidal risk by saturating the receptors
E) Doubling the dose will cause the drug to lose effect entirely through receptor down-regulation
ANSWER: C
Rationale:
A high-potency agent at a standard dose typically already occupies D2 receptors near the upper end of the 65 to 80 percent therapeutic window; doubling the dose pushes occupancy past roughly 80 percent, where extrapyramidal symptoms rise steeply while antipsychotic benefit plateaus. The better course is to reassess adherence and diagnosis and consider a switch rather than escalate into the toxic range.
Option A: Option A is incorrect because efficacy plateaus above the window while side effects climb.
Option B: Option B is incorrect because higher occupancy raises, not lowers, prolactin and would not be the mechanism of benefit.
Option D: Option D is incorrect because higher occupancy increases, rather than eliminates, extrapyramidal risk.
Option E: Option E is incorrect because the drug does not abruptly lose effect; the real problem is added toxicity without added benefit.
11. A 45-year-old man with newly diagnosed schizophrenia and a family history of diabetes asks his physician to "just put me on the newest drug, since newer must be better." Drawing on comparative-effectiveness evidence and class adverse-effect profiles, which response best supports a rational, individualized selection?
A) Agree that the newest second-generation agent is categorically superior and start it without regard to his metabolic risk
B) Explain that first-generation agents are always superior and select one on that basis
C) State that all antipsychotics are identical, so the choice is arbitrary
D) Choose the agent with the highest prolactin elevation because that predicts efficacy
E) Explain that real-world comparative data such as CATIE showed a first-generation agent (perphenazine) performed comparably to several second-generation agents on all-cause discontinuation, while the metabolic burden is concentrated in second-generation agents such as olanzapine and clozapine; given his diabetes risk, selection should be individualized to his symptom profile and adverse-effect risks rather than defaulting to the newest drug
ANSWER: E
Rationale:
A rational, individualized selection draws on two facts together: CATIE showed the first-generation agent perphenazine performed comparably to several second-generation agents on all-cause discontinuation, and the metabolic burden is concentrated in second-generation agents such as olanzapine and clozapine. For a patient with elevated diabetes risk, this argues against reflexively choosing the newest drug and for matching the agent to his symptom profile and adverse-effect risks.
Option A: Option A is incorrect because it asserts a categorical superiority the evidence does not support and ignores his metabolic risk.
Option B: Option B is incorrect because it overstates first-generation superiority, which CATIE also did not establish.
Option C: Option C is incorrect because the agents differ substantially in receptor profiles and adverse effects.
Option D: Option D is incorrect because prolactin elevation is an adverse effect, not a marker of efficacy, and would be a poor selection criterion.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.